At least in part, such changes in the clinical course of DKD are likely a consequence of the introduction into clinical practice of blockers of the renin-angiotensin system (RAS), the increasing use of which has not translated into a lower prevalence of reduced GFR and DKD, and has only marginally decreased the incidence of ESKD [76]. This evidence concerns the gene REN and diabetic kidney disease.